再生医療の世界市場予測(〜2025):製品別(細胞療法(自家、同種)、幹細胞療法、組織工学、遺伝子治療)、用途別(創傷治療、筋骨格、腫瘍、歯科、眼)、地域別

◆英語タイトル:Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025
◆商品コード:BT 4419
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年9月30日
◆ページ数:160
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Marketsandmarkets社は再生医療の世界市場が2020年85億ドルから2025年179億ドルまで、年平均15.9%成長すると展望しています。本調査レポートでは、再生医療の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(組織工学製品、細胞療法、遺伝子治療、前駆細胞・幹細胞療法)分析、用途別(筋骨格系障害、腫瘍、創傷ケア、歯、眼障害)分析、地域別分析、競争状況、企業評価・情報など、以下の構成でお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・再生医療の世界市場規模:製品別(組織工学製品、細胞療法、遺伝子治療、前駆細胞・幹細胞療法)
・再生医療の世界市場規模:用途別(筋骨格系障害、腫瘍、創傷ケア、歯、眼障害)
・再生医療の世界市場規模:地域別
・競争状況
・企業評価・情報
【レポートの概要】

“The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% during the forecast period.” Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

“The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period”
Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

“Oncology segment accounted for highest CAGR”
Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

“Europe: The fastest-growing region regenerative medicine market”
The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, and Rest of the World – 12%

Lits of companies Profiled in the Report:
• 3M (US)
• Allergan plc (Ireland)
• Amgen, Inc. (US)
• Aspect Biosystems (Canada)
• bluebird bio (US)
• Kite Pharma (US)
• Integra LifeSciences Holdings Corporation (US)
• MEDIPOST Co., Ltd. (South Korea)
• Medtronic plc (Ireland)
• Anterogen Co., Ltd. (South Korea)
• MiMedx Group (US)
• Misonix (US)
• Novartis AG (Switzerland)
• Organogenesis Inc. (US)
• Orthocell Limited (Australia)
• Corestem, Inc. (South Korea)
• Spark Therapeutics (US)
• APAC Biotech (India)
• Shenzhen Sibiono GeneTech Co., Ltd. (China)
• Smith & Nephew plc (UK)
• Stryker Corporation (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Tego Science (South Korea)
• Vericel Corporation (US)
• Zimmer Biomet (US)

Research Coverage:
This report provides a detailed picture of the global regenerative medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

【レポートの目次】

1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
FIGURE 1 INCLUSIONS & EXCLUSIONS 25
1.2.1 MARKETS COVERED 25
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 26
1.4 LIMITATIONS 26
1.5 STAKEHOLDERS 26
1.6 REPORT COMPARISON WITH THE MARCH 2019 EDITION 27
1.6.1 SUMMARY OF CHANGES 27
1.6.2 LIMITATIONS OF THE CURRENT EDITION 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 2 RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 28
2.1.1.1 Key data from secondary sources 29
2.1.2 PRIMARY DATA 30
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 31
2.2.1 BOTTOM-UP APPROACH 31
FIGURE 4 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH 32
2.2.2 TOP-DOWN APPROACH 32
FIGURE 5 REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH 32
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 33
FIGURE 6 DATA TRIANGULATION METHODOLOGY 33
2.4 ASSUMPTIONS FOR THE STUDY 34
3 EXECUTIVE SUMMARY 35
FIGURE 7 REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 35
FIGURE 8 REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2020 VS. 2025 (USD MILLION) 36
FIGURE 9 REGENERATIVE MEDICINE MARKET, BY REGION,
2020 VS. 2025 (USD MILLION) 36

4 PREMIUM INSIGHTS 38
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW 38
FIGURE 10 GROWING INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 38
4.2 CELL THERAPIES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION) 39
FIGURE 11 AUTOLOGOUS CELL THERAPIES TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN THE FORECAST PERIOD 39
4.3 REGENERATIVE MEDICINE MARKET SHARE, BY APPLICATION, 2020 VS. 2025 39
FIGURE 12 MUSCULOSKELETAL DISORDERS IS THE LARGEST APPLICATION SEGMENT OF THE REGENERATIVE MEDICINE MARKET 39
4.4 REGENERATIVE MEDICINE MARKET, BY REGION, 2020−2025 40
FIGURE 13 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 40
5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
FIGURE 14 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 41
5.2.1 DRIVERS 41
5.2.1.1 Rising prevalence of chronic diseases, genetic disorders, and cancer 41
FIGURE 15 INCIDENCE OF DIABETES, BY REGION, 2015 VS. 2040 (MILLION CASES) 42
TABLE 1 CANCER INCIDENCE AND MORTALITY, BY REGION, 2012–2035 42
TABLE 2 OBESITY-ASSOCIATED DEATH RATE (%), BY COUNTRY, 2017 43
5.2.1.2 Rising investments in regenerative medicine research 44
TABLE 3 TOTAL FUNDING, BY SOURCE TYPE, 2016–2019 (USD MILLION) 44
TABLE 4 FUNDING FROM CORPORATE PARTNERSHIPS, 2018–2019 (USD MILLION) 44
TABLE 5 FUNDRAISING THROUGH PUBLIC OFFERINGS (IPO & FOLLOW-ONS),
2018–2019 (USD MILLION) 45
TABLE 6 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY THE NIH UNDER
THE 21ST CENTURY CURES ACT, 2017–2019 (USD BILLION) 46
TABLE 7 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH (2017) 46
5.2.1.3 Growing pipeline of regenerative medicine products 46
TABLE 8 NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 2016–2018 46
TABLE 9 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET,
BY CLINICAL PHASE, 2018 VS. 2019 47
TABLE 10 NUMBER OF M&A TRANSACTIONS, 2016–2019 (USD MILLION) 48
5.2.2 RESTRAINTS 48
5.2.2.1 Ethical concerns related to the use of embryonic stem cells in research & development 48
5.2.2.2 High cost of cell and gene therapies 48
5.2.3 OPPORTUNITIES 49
5.2.3.1 Implementation of the 21st Century Cures Act 49
5.2.3.2 Rising demand for organ transplantations 49
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE REGENERATIVE MEDICINE MARKET 49
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT 51
6.1 INTRODUCTION 52
TABLE 11 FUNDING FOR REGENERATIVE MEDICINE PRODUCTS, 2019 (USD BILLION) 52
TABLE 12 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, 2018 VS. 2019 52
TABLE 13 NEW PRODUCT APPROVALS IN THE REGENERATIVE MEDICINE MARKET, 2018-2020 52
TABLE 14 REGENERATIVE MEDICINE MARKET: PRODUCT PIPELINE (2019) 53
TABLE 15 REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 54
6.2 TISSUE-ENGINEERED PRODUCTS 54
6.2.1 RISING PREVALENCE OF CHRONIC WOUNDS TO DRIVE THE MARKET GROWTH 54
TABLE 16 EXAMPLES OF COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS 55
TABLE 17 TISSUE-ENGINEERED PRODUCTS MARKET, BY REGION,
2018–2025 (USD MILLION) 55
TABLE 18 NORTH AMERICA: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 56
TABLE 19 EUROPE: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 56
TABLE 20 APAC: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 56
6.3 CELL THERAPIES 57
TABLE 21 COMMERCIALIZED CELL THERAPIES AVAILABLE IN THE MARKET 57
TABLE 22 CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 58
TABLE 23 CELL THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION) 59
TABLE 24 NORTH AMERICA: CELL THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 59
TABLE 25 EUROPE: CELL THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 59
TABLE 26 APAC: CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 60
6.3.1 AUTOLOGOUS THERAPIES 60
6.3.1.1 Autologous therapies segment to register the highest growth in the cell therapies market 60
TABLE 27 EXAMPLES OF COMMERCIALIZED AUTOLOGOUS CELL THERAPIES 60
TABLE 28 AUTOLOGOUS THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION) 61
TABLE 29 NORTH AMERICA: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 61
TABLE 30 EUROPE: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 61
TABLE 31 APAC: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 62
6.3.2 ALLOGENEIC THERAPIES 62
6.3.2.1 Rising incidence of chronic conditions to drive the market growth 62
TABLE 32 EXAMPLES OF COMMERCIALIZED ALLOGENEIC CELL THERAPIES 62
TABLE 33 ALLOGENEIC THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION) 63
TABLE 34 NORTH AMERICA: ALLOGENEIC THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 63
TABLE 35 EUROPE: ALLOGENEIC THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 63
TABLE 36 APAC: ALLOGENEIC THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 64
6.4 GENE THERAPIES 64
6.4.1 GROWING NUMBER OF CANCER CASES TO DRIVE MARKET GROWTH 64
TABLE 37 EXAMPLES OF COMMERCIALIZED GENE THERAPIES 64
TABLE 38 GENE THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION) 65
TABLE 39 NORTH AMERICA: GENE THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 65
TABLE 40 EUROPE: GENE THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 65
TABLE 41 APAC: GENE THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 66
6.5 PROGENITOR & STEM CELL THERAPIES 66
6.5.1 GROWING PRODUCT PIPELINE TO SUPPORT THE GROWTH OF THIS SEGMENT 66
TABLE 42 EXAMPLES OF COMMERCIALIZED PROGENITOR & STEM CELL THERAPIES 66
TABLE 43 PROGENITOR & STEM CELL THERAPIES MARKET, BY REGION,
2018–2025 (USD MILLION) 67
TABLE 44 NORTH AMERICA: PROGENITOR & STEM CELL THERAPIES MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 67
TABLE 45 EUROPE: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 67
TABLE 46 APAC: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 68
7 REGENERATIVE MEDICINE MARKET, BY APPLICATION 69
7.1 INTRODUCTION 70
TABLE 47 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS,
BY APPLICATION, 2018 VS. 2019 70
TABLE 48 REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 71
7.2 MUSCULOSKELETAL DISORDERS 71
7.2.1 INCREASING PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT 71
TABLE 49 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2018–2025 (USD MILLION) 72
TABLE 50 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION) 72
TABLE 51 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION) 73
TABLE 52 APAC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION) 73

7.3 ONCOLOGY 73
7.3.1 INCREASING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH 73
TABLE 53 NUMBER OF PATIENTS, BY TYPE OF CANCER, 2012–2030 74
TABLE 54 INDICATIVE LIST OF FEW COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR THE TREATMENT OF CANCER 75
TABLE 55 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION,
2018–2025 (USD MILLION) 76
TABLE 56 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,
BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 57 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 58 APAC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD MILLION) 77
7.4 WOUND CARE 77
7.4.1 RISING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE THE GROWTH OF THIS SEGMENT 77
TABLE 59 REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS 78
TABLE 60 REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION,
2018–2025 (USD MILLION) 78
TABLE 61 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR WOUND CARE,
BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 62 EUROPE: REGENERATIVE MEDICINE MARKET FOR WOUND CARE,
BY COUNTRY, 2018–2025 (USD MILLION) 79
TABLE 63 APAC: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018–2025 (USD MILLION) 79
7.5 DENTAL 79
7.5.1 RISING INCIDENCE OF ORAL DISORDERS TO DRIVE THE MARKET GROWTH 79
TABLE 64 REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 80
TABLE 65 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 81
TABLE 66 EUROPE: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS,
BY COUNTRY, 2018–2025 (USD MILLION) 81
TABLE 67 APAC: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS,
BY COUNTRY, 2018–2025 (USD MILLION) 81
7.6 OCULAR DISORDERS 82
7.6.1 RISING PRODUCT APPROVALS TO DRIVE MARKET GROWTH 82
TABLE 68 REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY REGION, 2018–2025 (USD MILLION) 82
TABLE 69 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION) 82
TABLE 70 EUROPE: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS,
BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 71 APAC: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS,
BY COUNTRY, 2018–2025 (USD MILLION) 83

7.7 OTHER APPLICATIONS 83
TABLE 72 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 84
TABLE 73 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 84
TABLE 74 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2018–2025 (USD MILLION) 85
TABLE 75 APAC: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2018–2025 (USD MILLION) 85
8 REGENERATIVE MEDICINE MARKET, BY REGION 86
8.1 INTRODUCTION 87
TABLE 76 NUMBER OF PLAYERS IN THE REGENERATIVE MEDICINE MARKET,
BY REGION, 2018 VS. 2019 87
TABLE 77 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY REGION (2019) 87
TABLE 78 REGENERATIVE MEDICINE MARKET, BY REGION, 2018–2025 (USD MILLION) 88
8.2 NORTH AMERICA 88
FIGURE 16 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 89
TABLE 79 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 89
TABLE 80 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 90
TABLE 81 NORTH AMERICA: CELL THERAPIES MARKET, BY TYPE,
2018–2025 (USD MILLION) 90
TABLE 82 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 90
8.2.1 US 91
8.2.1.1 Growing product pipeline to drive the market in the US 91
TABLE 83 PRODUCTS ANTICIPATED FOR APPROVALS IN THE US IN 2020 91
TABLE 84 PRODUCTS ANTICIPATED FOR FILINGS IN THE US IN 2020 91
TABLE 85 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 92
TABLE 86 US: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 92
TABLE 87 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 93
8.2.2 CANADA 93
8.2.2.1 Increasing investments in R&D to drive market growth 93
TABLE 88 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 94
TABLE 89 CANADA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 90 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 94
8.3 EUROPE 95
TABLE 91 EUROPE: RESEARCH FUNDING OVERVIEW (2017) 95
TABLE 92 PRODUCTS ANTICIPATED FOR APPROVALS IN EUROPE IN 2020 95
TABLE 93 PRODUCTS ANTICIPATED FOR FILINGS IN EUROPE IN 2020 96
TABLE 94 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 96
TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 96
TABLE 96 EUROPE: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 97 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 97
8.3.1 UK 97
8.3.1.1 Rising prevalence of chronic conditions to drive market growth in
the UK 97
TABLE 98 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 98
TABLE 99 UK: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 98
TABLE 100 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 98
8.3.2 GERMANY 99
8.3.2.1 Rising healthcare expenditure to propel market growth 99
TABLE 101 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 99
TABLE 102 GERMANY: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 103 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 100
8.3.3 FRANCE 100
8.3.3.1 Rising R&D expenditure, a major growth driver in France 100
TABLE 104 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 101
TABLE 105 FRANCE: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 106 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 101
8.3.4 REST OF EUROPE 102
TABLE 107 ROE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 102
TABLE 108 ROE: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 109 ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 103
8.4 ASIA PACIFIC 103
FIGURE 17 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT 104
TABLE 110 APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 105
TABLE 111 APAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 105
TABLE 112 APAC: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 105
TABLE 113 APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 106

8.4.1 JAPAN 106
8.4.1.1 Comparatively lenient regulations and rising geriatric population to drive market growth 106
TABLE 114 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 107
TABLE 115 JAPAN: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 116 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 108
8.4.2 CHINA 108
8.4.2.1 Favorable investments and government support to drive market growth in China 108
TABLE 117 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 108
TABLE 118 CHINA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 119 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 109
8.4.3 AUSTRALIA 109
8.4.3.1 Strong research base and availability of funds to drive market growth 109
TABLE 120 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 110
TABLE 121 AUSTRALIA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 122 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 111
8.4.4 ROAPAC 111
TABLE 123 ROAPAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 112
TABLE 124 ROAPAC: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION) 112
TABLE 125 ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 112
8.5 REST OF THE WORLD 113
TABLE 126 ROW: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 113
TABLE 127 ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 114
9 COMPETITIVE LANDSCAPE 115
9.1 OVERVIEW 115
FIGURE 18 KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET (JANUARY 2017 –AUGUST 2020) 115
9.2 CELL THERAPY MARKET SHARE ANALYSIS 116
FIGURE 19 CELL THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019 116
9.3 GENE THERAPY MARKET SHARE ANALYSIS 116
FIGURE 20 GENE THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019 116
9.4 TISSUE ENGINEERING MARKET RANKING 117
FIGURE 21 TISSUE ENGINEERING MARKET RANKING, 2019 117
9.5 COMPETITIVE SCENARIO 117
9.5.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 117
TABLE 128 PRODUCT LAUNCHES & REGULATORY APPROVALS
(JANUARY 2017–AUGUST 2020) 117
9.5.2 COLLABORATIONS 118
TABLE 129 COLLABORATIONS (JANUARY 2017–AUGUST 2020) 118
9.5.3 ACQUISITIONS 118
TABLE 130 ACQUISITIONS (JANUARY 2017–AUGUST 2020) 118
9.5.4 EXPANSIONS 118
TABLE 131 EXPANSIONS (JANUARY 2017–AUGUST 2020) 118
10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 119
10.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY 119
10.1.1 VENDOR INCLUSION CRITERIA 119
10.1.2 STARS 119
10.1.3 EMERGING LEADERS 119
10.1.4 PERVASIVE 119
10.1.5 PARTICIPANTS 120
FIGURE 22 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 120
10.2 COMPANY EVALUATION MATRIX FOR START-UPS (2019) 121
10.2.1 PROGRESSIVE COMPANIES 121
10.2.2 RESPONSIVE COMPANIES 121
10.2.3 STARTING BLOCKS 121
10.2.4 DYNAMIC COMPANIES 121
FIGURE 23 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019 122
10.3 COMPANY PROFILES 123
(Business overview, Products offered, Recent developments, MNM view)*
10.3.1 SMITH & NEPHEW PLC 123
FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2019) 123
10.3.2 VERICEL CORPORATION 125
FIGURE 25 VERICEL CORPORATION: COMPANY SNAPSHOT (2019) 125
10.3.3 INTEGRA LIFESCIENCES HOLDINGS CORPORATION 127
FIGURE 26 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019) 127
10.3.4 MIMEDX GROUP 129
FIGURE 27 MIMEDX GROUP: COMPANY SNAPSHOT (2019) 129
10.3.5 NOVARTIS AG 130
FIGURE 28 NOVARTIS: COMPANY SNAPSHOT (2019) 130
10.3.6 STRYKER CORPORATION 132
FIGURE 29 STRYKER CORPORATION: COMPANY SNAPSHOT (2019) 132
10.3.7 ORGANOGENESIS INC. 134
FIGURE 30 ORGANOGENESIS: COMPANY SNAPSHOT (2019) 134
10.3.8 MEDIPOST CO., LTD. 136
FIGURE 31 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2019) 136
10.3.9 3M GROUP 138
FIGURE 32 3M GROUP: COMPANY SNAPSHOT (2019) 138
10.3.10 MISONIX 140
FIGURE 33 MISONIX: COMPANY SNAPSHOT (2019) 140
10.3.11 ZIMMER BIOMET 141
FIGURE 34 ZIMMER BIOMET: COMPANY SNAPSHOT (2019) 141
10.3.12 MEDTRONIC PLC 143
FIGURE 35 MEDTRONIC PLC: COMPANY SNAPSHOT (2019) 143
10.3.13 AMGEN, INC. 145
FIGURE 36 AMGEN, INC.: COMPANY SNAPSHOT (2019) 145
10.3.14 ALLERGAN 146
FIGURE 37 ALLERGAN: COMPANY SNAPSHOT (2019) 146
10.3.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED 148
FIGURE 38 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2019) 148
10.3.16 ORTHOCELL LTD. 149
10.3.17 TEGO SCIENCE, INC. 150
10.3.18 CORESTEM, INC. 151
10.3.19 ANTEROGEN CO., LTD. 152
10.3.20 BLUEBIRD BIO 153
10.3.21 SPARK THERAPEUTICS 154
10.3.22 KITE PHARMA 155
10.3.23 APAC BIOTECH 156
10.3.24 SHENZHEN SIBIONO GENETECH CO., LTD. 157
10.3.25 ASPECT BIOSYSTEMS 158
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
11 APPENDIX 159
11.1 INSIGHTS FROM INDUSTRY EXPERTS 159
11.2 DISCUSSION GUIDE 160
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 162
11.4 AVAILABLE CUSTOMIZATIONS 164
11.5 RELATED REPORTS 164
11.6 AUTHOR DETAILS 165



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[再生医療の世界市場予測(〜2025):製品別(細胞療法(自家、同種)、幹細胞療法、組織工学、遺伝子治療)、用途別(創傷治療、筋骨格、腫瘍、歯科、眼)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆